{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:26:49Z","timestamp":1771302409254,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cpcardiol.2022.101503","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T23:31:11Z","timestamp":1668641471000},"page":"101503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acute Coronary Syndromes in Antiphospholipid Syndrome-above Suspicion: A Systematic Review"],"prefix":"10.1016","volume":"48","author":[{"given":"Vasileios","family":"Nevras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7312-0976","authenticated-orcid":false,"given":"Nikias","family":"Milaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Katsioulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoi","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotirios","family":"Tsalamandris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Gkounti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sideris","family":"Skevos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101503_bib0001","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0002","series-title":"Antiphospholipid syndrome in systemic autoimmune diseases","author":"Cervera","year":"2009"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0003","doi-asserted-by":"crossref","first-page":"1312e7","DOI":"10.1136\/ard.2003.014175","article-title":"Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients","volume":"63","author":"Cervera","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0004","doi-asserted-by":"crossref","unstructured":"Mehrania T, Petri M. Epidemiology of the antiphospholipid syndrome. Elsevier, 2009.","DOI":"10.1016\/S1571-5078(08)00402-9"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0005","doi-asserted-by":"crossref","unstructured":"Durcan L, Petri M., Cervera R, Espinosa, Khamashta MA (eds), Antiphospholipid syndrome in systemic autoimmune diseases, 2nd edition. Elsevier, 2016; 17\u201330.","DOI":"10.1016\/B978-0-444-63655-3.00002-8"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0006","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0007","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J, Autoimmun,"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0008","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1542\/peds.2008-1209","article-title":"Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry","volume":"122","author":"Avcin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0009","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classificationcriteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0011","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0012","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1055\/s-0038-1648517","article-title":"Beta 2-glycoprotein I deficiency and the risk of thrombosis","volume":"67","author":"Bancsi","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0013","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2009.07831.x","article-title":"Genetic risk. factors of thrombosis in the antiphospholipid syndrome","volume":"147","author":"Castro-Marrero","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0014","article-title":"Diagnosing antiphospholipid syndrome: \u201cextra-criteria\u201d manifestations and technical advances","volume":"13","author":"Amigo","year":"2017","journal-title":"Nature Rev Rheumatol"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0015","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0016","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0017","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MCA.0000000000000476","article-title":"Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review","volume":"28","author":"Nazir","year":"2017","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0018","doi-asserted-by":"crossref","unstructured":"Font J, Cervera R. Cardiac manifestations in antiphospholipid syndrome. Khamashta MA, editor. Hughes Syndrome. 2nd ed. Singapore: Springer, 2006; 41\u201353.","DOI":"10.1007\/1-84628-009-5_5"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/pmj.78.915.27","article-title":"Acute myocardial infarction in young adults:causes and management","volume":"78","author":"Osula","year":"2002","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0020","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/ard.2008.093179","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicenter prospective study of 1000 patients","volume":"68","author":"Cervera","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12016-011-8268-9","article-title":"Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome","volume":"44","author":"Gualtierotti","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0022","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Joint ESC\/ACCF\/AHA\/WHF Task Force for the universal Definition of myocardial infarction. Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0023","doi-asserted-by":"crossref","unstructured":"Doria A, Sarzi-Puttini P. Heart, rheumatism and autoimmunity: an old intriguing link. Lupus 2005;14643\u2013645.","DOI":"10.1191\/0961203305lu2191ed"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0024","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.99.17.2227","article-title":"Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression","volume":"99","author":"George","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1191\/0961203305lu2211oa","article-title":"Oxidized LDL\/beta2-glycoprotein I complexes: new aspects in atherosclerosis","volume":"14","author":"Matsuura","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0026","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1136\/ard.2004.023952","article-title":"Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data","volume":"64","author":"Ames","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0027","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/rheumatology\/keh722","article-title":"Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model","volume":"44","author":"Delgado Alves","year":"2005","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0889-857X(05)70135-6","article-title":"Hopkins lupus cohort. 1999 update","volume":"26","author":"Petri","year":"2000","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0029","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.2003.016204","article-title":"Prevalence of an abnormal ankle\u2013brachial index in patients with primary antiphospholipid syndrome: preliminary data","volume":"64","author":"Baron","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0031","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1191\/0961203302lu165oa","article-title":"Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies","volume":"11","author":"Ames","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0032","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ard.62.7.607","article-title":"Increased carotid artery intima-mediathickness may be associated with stroke in primary antiphospholipid syndrome","volume":"62","author":"Medina","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0033","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0140-6736(92)91057-F","article-title":"Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and nonhaemorrhagic stroke","volume":"339","author":"Sletnes","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0034","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/0002-9149(90)91439-D","article-title":"Prevalence of anticardiolipin antibodies in coronary artery disease","volume":"65","author":"De Caterina","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14740\/cr661w","article-title":"Coronary artery thromboses, stent thrombosis and antiphospholipid antibody syndrome: case report","volume":"9","author":"Correia","year":"2018","journal-title":"Cardiol Res"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0036","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0037","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/096120339500400413","article-title":"The presence of antiphospholipid antibodies in acute myocardial infarction","volume":"4","author":"Adler","year":"1995","journal-title":"Lupus"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0038","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.CIR.91.1.23","article-title":"Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men","volume":"91","author":"Vaarala","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0039","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.semarthrit.2017.10.015","article-title":"Carotid and femoral atherosclerosisin antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study","volume":"47","author":"Kravvariti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0040","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/j.1538-7836.2007.02763.x","article-title":"Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women","volume":"5","author":"Meroni","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipidantibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0042","doi-asserted-by":"crossref","first-page":"380\u2014384","DOI":"10.1159\/000176429","article-title":"Anticardiolipin antibodies in patients with unstable angina","volume":"84","author":"Diaz","year":"1994","journal-title":"Cardiology"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0043","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08916939908994766","article-title":"High prevalence of anti-beta2-glycoprotein I antibodies in patients with ischemic heart disease","volume":"30","author":"Farsi","year":"1999","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0044","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1161\/CIRCULATIONAHA.113.001258","article-title":"Unstable angina: is it time for a requiem?","volume":"127","author":"Braunwald","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0045","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.114.011201","article-title":"Systematic review of patients presenting with suspected myocardial infarction and non-obstructive coronary arteries","author":"Pasupathy","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcha.2018.12.015","article-title":"Prevalence of myocardial infarction with non-obstructive coronary arteries (MINOCA) amongst acute coronary syndrome in patients with antiphospholipid syndrome","author":"Gandhi","year":"2019","journal-title":"IJC Heart & Vasculature"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0047","first-page":"e523","article-title":"Spontaneous coronary artery dissection:current state of the science: ascientific statement from the","volume":"137","author":"Hayes","year":"2018","journal-title":"Am Heart Assoc. Circ"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227674","article-title":"Chronic spontaneous coronary artery dissection in association with antiphospholipid syndrome presenting as stable angina","volume":"12","author":"Chongprasertpon","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0049","first-page":"2016","article-title":"Diagnosis and management of the Antiphospholipid Syndrome","author":"Garcia","year":"2019","journal-title":"The New Eng J Med"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0050","article-title":"Treatment failures of direct oral Anticoagulants [published online ahead of print, 2019 Oct 9]","author":"Kajy","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0051","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0052","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/hrt.79.1.96","article-title":"Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA","volume":"79","author":"Takeuchi","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0053","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000338347","article-title":"Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention","volume":"122","author":"Perl","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0054","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.autrev.2014.11.003","article-title":"Antiphospholipid syndrome and the heart: a case series and literature review","volume":"14","author":"Denas","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000177119","article-title":"Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome","volume":"87","author":"Ho","year":"1996","journal-title":"Cardiology"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0056","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood.V86.10.3685.bloodjournal86103685","article-title":"Antiphospholipid antibodies and venous thromboembolism","volume":"86","author":"Ginsberg","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0057","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1055\/s-0038-1650686","article-title":"Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies","volume":"76","author":"Horbach","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0058","article-title":"Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors","author":"Andrade","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0059","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0060","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the Global Anti-Phospholipid Syndrome Score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0061","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort","volume":"49","author":"Radin","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0062","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0063","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2022.101503_bib0064","article-title":"Apixaban for the secondary prevention of Thromboembolism among patients with the AntiPhospholipid Syndrome (ASTRO-APS)","author":"Woller","year":"2019","journal-title":"Clinicaltrials.gov Accessed"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:58:33Z","timestamp":1758938313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622004005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0146280622004005"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101503","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Coronary Syndromes in Antiphospholipid Syndrome-above Suspicion: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101503"}}